139 related articles for article (PubMed ID: 38881076)
1. Canagliflozin/metformin Fixed-dose Combination: National Evidence, Global Relevance.
Kalra S; Kapoor N
J Assoc Physicians India; 2024 Apr; 72(4):11. PubMed ID: 38881076
[No Abstract] [Full Text] [Related]
2. Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
Davidson JA; Sloan L
Adv Ther; 2017 Jan; 34(1):41-59. PubMed ID: 27854055
[TBL] [Abstract][Full Text] [Related]
3. In brief: Canagliflozin and lower limb amputations.
Med Lett Drugs Ther; 2020 Sep; 62(1607):152. PubMed ID: 32960870
[No Abstract] [Full Text] [Related]
4. Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.
Polidori D; Capuano G; Qiu R
Diabetes Obes Metab; 2016 Apr; 18(4):348-54. PubMed ID: 26661906
[TBL] [Abstract][Full Text] [Related]
5. Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes.
Rosenstock J; Chuck L; González-Ortiz M; Merton K; Craig J; Capuano G; Qiu R
Diabetes Care; 2016 Mar; 39(3):353-62. PubMed ID: 26786577
[TBL] [Abstract][Full Text] [Related]
6. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Rosenstock J; Aggarwal N; Polidori D; Zhao Y; Arbit D; Usiskin K; Capuano G; Canovatchel W;
Diabetes Care; 2012 Jun; 35(6):1232-8. PubMed ID: 22492586
[TBL] [Abstract][Full Text] [Related]
7. Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.
de Winter W; Dunne A; de Trixhe XW; Devineni D; Hsu CH; Pinheiro J; Polidori D
Br J Clin Pharmacol; 2017 May; 83(5):1072-1081. PubMed ID: 28138980
[TBL] [Abstract][Full Text] [Related]
8. Fixed-dose combination of ertugliflozin and metformin hydrochloride for the treatment of type 2 diabetes.
Frias JP
Expert Rev Endocrinol Metab; 2019 Mar; 14(2):75-83. PubMed ID: 30724637
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
[TBL] [Abstract][Full Text] [Related]
11. Canagliflozin + metformin ER for the treatment of type 2 diabetes: the evidence to date.
Tomlinson B; Li YH
Expert Opin Pharmacother; 2023; 24(18):1937-1947. PubMed ID: 37881952
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin: A Review in Type 2 Diabetes.
Deeks ED; Scheen AJ
Drugs; 2017 Sep; 77(14):1577-1592. PubMed ID: 28836175
[TBL] [Abstract][Full Text] [Related]
13. Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
Okahata S; Sakamoto K; Mitsumatsu T; Kondo Y; Tanaka S; Shiba T
Diabetes Obes Metab; 2019 Feb; 21(2):388-392. PubMed ID: 30146790
[TBL] [Abstract][Full Text] [Related]
14. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials.
Seko Y; Sumida Y; Sasaki K; Itoh Y; Iijima H; Hashimoto T; Ishii S; Inagaki N
J Gastroenterol; 2018 Jan; 53(1):140-151. PubMed ID: 28669071
[TBL] [Abstract][Full Text] [Related]
15. Should sodium-glucose co-transporter-2 inhibitors be considered as first-line oral therapy for people with type 2 diabetes?
Khunti K; Seidu S; Davies MJ
Diabetes Obes Metab; 2019 Feb; 21(2):207-209. PubMed ID: 30178516
[No Abstract] [Full Text] [Related]
16. SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?
Bloomgarden ZT; Handelsman Y
Endocr Pract; 2015 Dec; 21(12):1442-4. PubMed ID: 26484408
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
Lavalle-González FJ; Eliaschewitz FG; Cerdas S; Chacon Mdel P; Tong C; Alba M
Curr Med Res Opin; 2016; 32(3):427-39. PubMed ID: 26579834
[TBL] [Abstract][Full Text] [Related]
18. Investigation of efficacy and safety of low-dose sodium glucose transporter 2 inhibitors and differences between two agents, canagliflozin and ipragliflozin, in patients with type 2 diabetes mellitus.
Sugimoto K; Abe I; Minezaki M; Takashi Y; Ochi K; Fujii H; Ohishi H; Yamao Y; Kudo T; Ohe K; Abe M; Ohnishi Y; Shinagawa T; Mukoubara S; Kobayashi K
Drug Discov Ther; 2019; 13(6):322-327. PubMed ID: 31956230
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Cefalu WT; Leiter LA; Yoon KH; Arias P; Niskanen L; Xie J; Balis DA; Canovatchel W; Meininger G
Lancet; 2013 Sep; 382(9896):941-50. PubMed ID: 23850055
[TBL] [Abstract][Full Text] [Related]
20. Comparison chart: SGLT2 inhibitors.
Med Lett Drugs Ther; 2020 Nov; 62(1611):e2-e4. PubMed ID: 33429417
[No Abstract] [Full Text] [Related]
[Next] [New Search]
